This document has been prepared by the European Molecular Biology Laboratory to provide a summary of epidemiological information for public health officials and governments. The lead author is Dr Moritz Gerstung, of EMBL\u2019s European Bioinformatics Institute (EMBL-EBI) at the Wellcome Genome Campus in the United Kingdom. Other contributors include Deputy Director General and EMBL-EBI Director Dr Ewan Birney FRS and EMBL-EBI Director Dr Rolf Apweiler.<\/p>\n\n\n\n
The B.1.1.7 lineage was first discovered on September 20 in Kent by the U.K.\u2019s Coronavirus Genome consortium COG-UK, which has sequenced more than 170,000 SARS-CoV-2 genomes [1<\/a>,2<\/a>]. It has since spread to nearly every British local authority and 57 other countries [3<\/a>]. While B.1.1.7 is not evidently causing more severe disease [4<\/a>], it is approximately 30-50% more transmissible as evidenced by epidemiology [5<\/a>,6<\/a>] and contact tracing [7<\/a>]. This higher transmissibility has led to a massive surge in cases in England, which has pushed the health care system to its limits and led to declaration of a third national strict lockdown [8<\/a>] on January 4, 2021.<\/p>\n\n\n\n The availability of detailed genomic surveillance information enabled reconstruction of B.1.1.7\u2019s spread in great detail. Of particular concern is its capability to proliferate (R>1) in nearly every English local authority during the second national lockdown from November 5 to December 2 throughout which B.1.1.7 cases increased three- to fourfold \u2013 even though mostly at low absolute numbers at the time and so not affecting the aggregate case levels [9<\/a>]. It is important to note that the UK November lockdown did lead to suppression of other SARS-CoV-2 lineages (R<1) which at the time were predominant. The lockdown led to an overall case reduction of approximately 50% [9<\/a>]. Following the end of the lockdown, the pattern of faster proliferation was sustained throughout December, leading to a tenfold increase in B.1.1.7 cases in London, while other SARS-CoV-2 cases only grew 40% as observed in population testing data from the Office of National Statistics [10<\/a>].<\/p>\n\n\n\n While cases of B.1.1.7 exported to other countries will initially be in single numbers, B.1.1.7 cases can double weekly, as evidenced recently in Denmark, which does genomic surveillance of 10% of its SARS-CoV-2 samples [11<\/a>]. Coincidentally, B.1.1.7 can be detected by commercial qPCR assays due to its \u039469-70 deletion, leading to dropout of 1\/3 genomic regions tested in many laboratories as part of standard SARS-CoV-2 diagnostics [4<\/a>,12<\/a>]. The rate of \u039469-70 is low (0.5-5%) in other circulating SARS-CoV-2 lineages.<\/p>\n\n\n\n In summary, it is important to understand these new features of B.1.1.7:<\/p>\n\n\n\n Dieses Dokument wurde vom Europ\u00e4ischen Laboratorium f\u00fcr Molekularbiologie erstellt, um eine Zusammenfassung epidemiologischer Informationen f\u00fcr Beamte des \u00f6ffentlichen Gesundheitswesens und Regierungen bereitzustellen. Der Hauptautor ist Dr. Moritz Gerstung vom Europ\u00e4ischen Bioinformatik-Institut des EMBL (EMBL-EBI) am Wellcome Genome Campus in Gro\u00dfbritannien. Weitere Mitwirkende sind der stellvertretende Generaldirektor und EMBL-EBI-Direktor Dr. Ewan Birney FRS und EMBL-EBI-Direktor Dr. Rolf Apweiler.<\/p>\n\n\n\n Die B.1.1.7-Linie wurde erstmals am 20. September in Kent durch das britische Coronavirus-Genom-Konsortium COG-UK entdeckt, das bis heute mehr als 170.000 SARS-CoV-2-Genome sequenziert hat [1<\/a>,2<\/a>]. Inzwischen hat sich das Virus in fast allen britischen Kommunen und 57 weiteren L\u00e4ndern ausgebreitet [3<\/a>]. W\u00e4hrend B.1.1.7 offensichtlich keine schwereren Erkrankungen verursacht [4<\/a>], ist es ca. 30-50% ansteckender, wie durch Epidemiologie [5<\/a>,6<\/a>] und Kontaktverfolgung [7<\/a>] nachgewiesen werden konnte. Diese h\u00f6here Ansteckrate hat in England zu einem massiven Anstieg der F\u00e4lle gef\u00fchrt, der das Gesundheitssystem an seine Grenzen gebracht hat und dazu f\u00fchrte, dass am 4. Januar 2021 ein dritter nationaler strenger Lockdown [8<\/a>] ausgerufen wurde.<\/p>\n\n\n\n Die Verf\u00fcgbarkeit von detaillierten genomischen Daten erm\u00f6glichte eine sehr genaue Rekonstruktion der Ausbreitung von B.1.1.7. Besonders besorgniserregend ist die F\u00e4higkeit des Erregers, sich w\u00e4hrend der zweiten landesweiten Abriegelung vom 5. November bis 2. Dezember in fast allen englischen Kommunen zu verbreiten (R>1). W\u00e4hrend dieser Zeit stiegen die B.1.1.7-F\u00e4lle um das Drei- bis Vierfache an \u2013 auch wenn die absoluten Zahlen zu diesem Zeitpunkt meist niedrig waren und somit die Gesamtfallzahlen nur gering beeinflusst wurden [9<\/a>]. Es ist wichtig anzumerken, dass der britische Lockdown im November zu einer Unterdr\u00fcckung anderer SARS-CoV-2-Linien (R<1) f\u00fchrte, die zu dieser Zeit vorherrschend waren. Der Lockdown f\u00fchrte zu einer Reduktion der F\u00e4lle um insgesamt ca. 50% [9<\/a>]. Nach dem Ende des Lockdowns setzte sich das Muster der schnelleren Vermehrung den ganzen Dezember \u00fcber fort, was zu einem zehnfachen Anstieg der B.1.1.7-F\u00e4lle in London f\u00fchrte, w\u00e4hrend andere SARS-CoV-2-F\u00e4lle nur um 40 % zunahmen, wie in den repr\u00e4sentativen Populationsstudien des Office of National Statistics beobachtet wurde [10<\/a>].<\/p>\n\n\n\n W\u00e4hrend F\u00e4lle von B.1.1.7, die in andere L\u00e4nder exportiert werden, anf\u00e4nglich in einfacher Zahl auftreten, k\u00f6nnen sich die B.1.1.7-F\u00e4lle w\u00f6chentlich verdoppeln, wie k\u00fcrzlich in D\u00e4nemark gezeigt wurde, welches eine genomische Untersuchung von 10 % seiner SARS-CoV-2-Proben durchf\u00fchrt [11<\/a>]. Zuf\u00e4lligerweise kann B.1.1.7 aufgrund seiner \u039469-70-Deletion mit kommerziellen qPCR-Assays nachgewiesen werden, was zu einem Dropout von 1\/3 der genomischen Regionen f\u00fchrt, die in vielen Labors als Teil der Standard-SARS-CoV-2-Diagnostik getestet werden [4<\/a>,12<\/a>]. Die Rate von \u039469-70 ist bei anderen zirkulierenden SARS-CoV-2-Linien gering (0,5-5 %).<\/p>\n\n\n\n Zusammenfassend ist es wichtig, diese neuen Merkmale von B.1.1.7 zu verstehen:<\/p>\n\n\n\n Ce document a \u00e9t\u00e9 pr\u00e9par\u00e9 par le Laboratoire Europ\u00e9en de Biologie Mol\u00e9culaire (EMBL) afin de fournir un r\u00e9sum\u00e9 des informations \u00e9pid\u00e9miologiques aux responsables de la sant\u00e9 publique et aux gouvernements. L’auteur principal est le Dr Moritz Gerstung, de l’Institut Europ\u00e9en de Bioinformatique de l’EMBL (EMBL-EBI) au Wellcome Genome Campus au Royaume-Uni. Parmi les autres contributeurs figurent le Dr Ewan Birney FRS, Directeur G\u00e9n\u00e9ral Adjoint et Directeur de l’EMBL-EBI, et le Dr Rolf Apweiler, Directeur de l’EMBL-EBI.<\/p>\n\n\n\n Le variant B.1.1.7 a \u00e9t\u00e9 d\u00e9couvert pour la premi\u00e8re fois le 20 septembre dans le Kent, gr\u00e2ce au s\u00e9quen\u00e7age de plus de 170 000 g\u00e9nomes du SARS-CoV-2 [1<\/a>,2<\/a>] par le consortium britannique COG-UK (Coronavirus Genome Consortium). Il s’est depuis propag\u00e9 dans presque toutes les collectivit\u00e9s locales britanniques et dans 57 autres pays [3<\/a>]. A l\u2019heure actuelle, il n\u2019y a pas d\u2019\u00e9vidence que B.1.1.7 soit \u00e0 l\u2019origine de formes plus graves de la maladie [4<\/a>]. Cependant, les \u00e9tudes \u00e9pid\u00e9miologiques [5<\/a>,6<\/a>] et la recherche des cas contacts montrent qu\u2019il est environ 30 \u00e0 50 % plus transmissible [7<\/a>]. Cette transmissibilit\u00e9 plus \u00e9lev\u00e9e a entra\u00een\u00e9 une augmentation massive des cas en Angleterre, ce qui a pouss\u00e9 le syst\u00e8me de sant\u00e9 \u00e0 ses limites et a conduit, le 4 janvier 2021, \u00e0 la mise en place d’un troisi\u00e8me confinement strict au niveau national [8<\/a>].<\/p>\n\n\n\n La disponibilit\u00e9 d’informations pr\u00e9cises sur la surveillance g\u00e9nomique a permis de reconstituer la propagation de B.1.1.7 de mani\u00e8re tr\u00e8s d\u00e9taill\u00e9e. Il est particuli\u00e8rement inqui\u00e9tant de constater sa capacit\u00e9 de prolif\u00e9ration (R>1) dans presque toutes les collectivit\u00e9s locales anglaises pendant le deuxi\u00e8me confinement national, du 5 novembre au 2 d\u00e9cembre. Durant cette p\u00e9riode, le nombre de cas de B.1.1.7 a \u00e9t\u00e9 multipli\u00e9 par trois ou quatre, m\u00eame si les chiffres absolus \u00e9taient alors faibles et n\u2019ont donc pas affect\u00e9 le nombre total de cas [9<\/a>]. Il est important de noter que le confinement de novembre au Royaume-Uni a entra\u00een\u00e9 la suppression d’autres variants du SARS-CoV-2 (R<1), qui \u00e9taient alors pr\u00e9dominants. Le confinement a conduit \u00e0 une r\u00e9duction globale du nombre de cas d’environ 50% [9<\/a>]. Apr\u00e8s la fin du confinement, le sch\u00e9ma de prolif\u00e9ration plus rapide s’est maintenu tout au long du mois de d\u00e9cembre, entra\u00eenant une multiplication par dix des cas de B.1.1.7 \u00e0 Londres, alors que les autres cas de SARS-CoV-2 n’ont augment\u00e9 que de 40 %, comme l’ont montr\u00e9 les donn\u00e9es obtenues par le Bureau de la Statistique Nationale (Office of National Statistics) lors de d\u00e9pistages de la population [10<\/a>].<\/p>\n\n\n\n Alors que le nombre de cas de B.1.1.7 export\u00e9s vers d’autres pays est initialement r\u00e9duit, ceux-ci peuvent doubler chaque semaine, comme l’a r\u00e9cemment d\u00e9montr\u00e9 le Danemark, qui effectue une surveillance g\u00e9nomique de 10 % de ses \u00e9chantillons de SARS-CoV-2 [11<\/a>] Par chance, B.1.1.7 peut \u00eatre d\u00e9tect\u00e9 par des tests qPCR commerciaux en raison de la d\u00e9l\u00e9tion de \u039469-70, qui entra\u00eene l\u2019\u00e9limination d’un tiers des r\u00e9gions g\u00e9nomiques test\u00e9es dans de nombreux laboratoires dans le cadre des diagnostics standard du SARS-CoV-2 [4<\/a>,12<\/a>]. Le taux de \u039469-70 est faible (0,5 \u00e0 5 %) dans les autres variants de SARS-CoV-2 en circulation. <\/p>\n\n\n\n En r\u00e9sum\u00e9, il est important de comprendre ces nouvelles caract\u00e9ristiques de B.1.1.7:<\/p>\n\n\n\n \u25cf Le virus B.1.1.7 a des propri\u00e9t\u00e9s biologiques diff\u00e9rentes de celles des variants pr\u00e9c\u00e9dents. Il est important de noter que les taux de transmission sont 30 \u00e0 50 % plus \u00e9lev\u00e9s, ce qui peut multiplier par six \u00e0 huit le nombre de cas sur un mois. Cela suscite de grandes inqui\u00e9tudes quant \u00e0 la vitesse \u00e0 laquelle la pand\u00e9mie va progresser. Actuellement, il n’y a pas de preuves d’un changement dans la gravit\u00e9 ou la progression de la maladie.<\/p>\n\n\n\n \u25cf La transmission du virus B.1.1.7 n’a pas \u00e9t\u00e9 contenue par le “confinement de novembre\u201d anglais, qui a r\u00e9duit par deux le nombre d’autres cas de SARS-CoV-2. <\/p>\n\n\n\n \u25cf Une pr\u00e9diction, quant \u00e0 la transmissibilit\u00e9 plus \u00e9lev\u00e9e de B.1.1.7, est qu’un confinement plus strict, suffisant pour r\u00e9duire de 90 % l’incidence des pr\u00e9c\u00e9dents cas de SARS-CoV-2 en un mois, ne peut r\u00e9duire l’incidence de B.1.1.7 que de 20 \u00e0 40 % sur la m\u00eame p\u00e9riode. <\/p>\n\n\n\n \u25cf Il s’\u00e9coule un temps consid\u00e9rable (~2 mois) entre le moment o\u00f9 le virus B.1.1.7 est signal\u00e9 pour la premi\u00e8re fois et celui o\u00f9 l’on constate son impact en raison du nombre total de cas, en particulier en pr\u00e9sence d’autres variants du virus en circulation. <\/p>\n\n\n\n \u25cf B.1.1.7 peut \u00eatre d\u00e9tect\u00e9 \u00e0 l’aide de certains tests qPCR disponibles via l\u2019absence de signal de d\u00e9tection du g\u00e8ne S.<\/p>\n\n\n Questo documento \u00e8 stato preparato dal Laboratorio Europeo di Biologia Molecolare (EMBL) per fornire una sintesi delle informazioni epidemiologiche per i funzionari della sanit\u00e0 pubblica e i governi. L’autore principale \u00e8 il dr. Moritz Gerstung, dell’Istituto Europeo di Bioinformatica dell’EMBL (EMBL-EBI) presso il Wellcome Genome Campus nel Regno Unito. Tra gli altri collaboratori vi sono il vicedirettore generale e direttore dell’EMBL-EBI, il dr. Ewan Birney FRS e il direttore dell’EMBL-EBI, il dr. Rolf Apweiler.<\/p>\n\n\n\n La variante B.1.1.7 \u00e8 stata scoperta per la prima volta il 20 settembre nel Kent dal consorzio britannico del Coronavirus Genome COG-UK, che ha sequenziato pi\u00f9 di 170.000 genomi di SARS-CoV-2 [1<\/a>,2<\/a>]. Da allora \u00e8 stato rilevato da quasi tutte le autorit\u00e0 locali britanniche e in altri 57 Paesi [3<\/a>]. La variante B.1.1.1.7 non ha dimostrato di provocare una malattia pi\u00f9 grave [4<\/a>], ma le evidenze epidemiologiche e il tracciamento dei contatti [7<\/a>] dimostrano un incremento di trasmissibilit\u00e0 di circa il 30-50% [5<\/a>,6<\/a>]. Questa maggiore trasmissibilit\u00e0 ha portato ad un massiccio aumento dei casi in Inghilterra, che ha spinto il sistema sanitario del paese ai suoi limiti e ha portato alla dichiarazione di un terzo lockdown nazionale [8<\/a>] il 4 gennaio 2021.<\/p>\n\n\n\n La disponibilit\u00e0 di informazioni dettagliate di sorveglianza genomica ha permesso di ricostruire la diffusione di B.1.1.7 in modo molto accurato. Desta preoccupazione la sua capacit\u00e0 di proliferare (R>1) in quasi tutte le regioni inglesi durante il secondo lockdown nazionale, dal 5 novembre al 2 dicembre, periodo in cui i casi di B.1.1.7 sono aumentati da tre a quattro volte – anche se in quel momento in numero assoluto di casi basso, che non hanno quindi inciso sul numero complessivo dei casi [9]. \u00c8 importante notare che il lockdown di novembre nel Regno Unito ha portato alla soppressione di altre varianti di SARS-CoV-2 (R<1) che all’epoca erano predominanti. Il lockdown ha portato a una riduzione complessiva dei casi di circa il 50% [9<\/a>]. Dopo la fine del lockdown, il modello di proliferazione pi\u00f9 rapida \u00e8 stato sostenuto per tutto il mese di dicembre, portando a un aumento di dieci volte dei casi di B.1.1.7 a Londra, mentre gli altri casi di SARS-CoV-2 sono cresciuti solo del 40%, come osservato nei dati dei test sulla popolazione dell’Office of National Statistics [10<\/a>].<\/p>\n\n\n\n Mentre i casi di B.1.1.7 esportati in altri Paesi saranno inizialmente poco rilevanti, questi possono raddoppiare settimanalmente, come dimostrato di recente in Danimarca, che effettua la sorveglianza genomica del 10% dei suoi campioni di SARS-CoV-2 [11<\/a>]. Per caso si \u00e8 scoperto che B.1.1.7 pu\u00f2 essere rilevato da saggi qPCR disponibili in commercio a causa della delezione \u039469-70, che porta all\u2019esclusione di 1\/3 delle regioni genomiche testate in molti laboratori come parte della diagnostica standard di SARS-CoV-2 [4<\/a>,12<\/a>]. In altre linee di SARS-CoV-2 circolanti, il tasso di delezione \u039469-70 \u00e8 basso (0,5-5%).<\/p>\n\n\n\n In sintesi, \u00e8 importante comprendere le seguenti caratteristiche specifiche di B.1.1.7:<\/p>\n\n\n\n Este documento ha sido preparado por el Laboratorio Europeo de Biolog\u00eda Molecular (EMBL) con el objetivo de proporcionar un resumen de informaci\u00f3n epidemiol\u00f3gica a los funcionarios de salud p\u00fablica y los gobiernos. Su autor principal es el Dr. Moritz Gerstung, del Instituto Europeo de Bioinform\u00e1tica de EMBL (EMBL-EBI) en el Wellcome Genome Campus en el Reino Unido. Otros contribuyentes incluyen al Dr. Ewan Birney, Director General Adjunto y director del EMBL-EBI, y al Dr. Rolf Apweiler, director del EMBL-EBI.<\/p>\n\n\n\n La variante B.1.1.7 fue descubierta por primera vez el 20 de septiembre en Kent por el consorcio del Genoma del Coronavirus del Reino Unido COG-UK, despu\u00e9s de haber secuenciado m\u00e1s de 170.000 genomas de SARS-CoV-2 [1<\/a>,2<\/a>]. Desde entonces, ha sido detectado por casi todas las autoridades locales brit\u00e1nicas y tambi\u00e9n por otros 57 pa\u00edses [3<\/a>]. Si bien no hay evidencia de que la B.1.1.7 est\u00e9 provocando una enfermedad m\u00e1s grave [4<\/a>], la epidemiolog\u00eda [5<\/a>,6<\/a>] y el rastreo de contactos [7<\/a>] han demostrado que es aproximadamente un 30-50% m\u00e1s transmisible. Esta mayor transmisibilidad ha causado un aumento masivo de casos en el pa\u00eds, lo que ha llevado al sistema de salud brit\u00e1nico a sus l\u00edmites y provocado la declaraci\u00f3n de un tercer confinamiento nacional estricto [8<\/a>] el 4 de enero de 2021.<\/p>\n\n\n\n La disponibilidad de informaci\u00f3n detallada de vigilancia gen\u00f3mica permiti\u00f3 la reconstrucci\u00f3n de la propagaci\u00f3n de la variante B.1.1.7 con gran precisi\u00f3n. De particular preocupaci\u00f3n es su capacidad de proliferar (R> 1) en casi todas las regiones inglesas durante el segundo confinamiento nacional entre el 5 de noviembre y el 2 de diciembre. Durante este periodo, los casos de B.1.1.7 aumentaron de tres a cuatro veces. Debido a que en su mayor\u00eda las cifras tuvieron valores absolutos bajos en ese momento, esto no afect\u00f3 significativamente el n\u00famero de casos agregados [9<\/a>]. Es importante se\u00f1alar que el confinamiento de noviembre en el Reino Unido condujo a la supresi\u00f3n de otros linajes de SARS-CoV-2 (R <1) que en ese momento eran predominantes. El confinamiento dio lugar a una reducci\u00f3n general de casos de aproximadamente el 50% [9<\/a>]. Tras el final del confinamiento, el patr\u00f3n de proliferaci\u00f3n m\u00e1s r\u00e1pida se mantuvo durante todo diciembre, lo que llev\u00f3 a un aumento de diez veces en el n\u00famero de casos de B.1.1.7 en Londres, mientras que los casos de SARS-CoV-2 que no presentaban la variante solo crecieron un 40%, como fue observado por la Oficina de Estad\u00edstica Nacional en los test a la poblaci\u00f3n [10<\/a>].<\/p>\n\n\n\n Aunque los casos de B.1.1.7 exportados a otros pa\u00edses inicialmente son muy escasos, la evidencia cient\u00edfica indica que los casos de B.1.1.7 pueden duplicarse semanalmente, como se ha mostrado recientemente en Dinamarca, donde se realiza vigilancia gen\u00f3mica del 10% de las muestras de SARS-CoV-2. [11<\/a>]. De casualidad, la variante B.1.1.7 se puede detectar mediante ensayos comerciales de qPCR debido a la deleci\u00f3n \u039469-70, que lleva a la eliminaci\u00f3n de 1\/3 de las regiones gen\u00f3micas analizadas en muchos laboratorios como parte de los diagn\u00f3sticos est\u00e1ndar de SARS-CoV-2 [4<\/a>,12<\/a>]. En otras variantes circulantes de SARS-CoV-2, la tasa de esta deleci\u00f3n (\u039469-70) es baja (0.5-5%).<\/p>\n\n\n\n En resumen, es importante comprender las siguientes caracter\u00edsticas nuevas de la variante B.1.1.7 de SARS-CoV-2:<\/p>\n\n\n\n A note on the coronavirus variant B.1.1.7, which has first been described in the U.K. and has spread to 57 countries. The note summarises epidemiological information about the spread of B.1.1.7 in the U.K. collated and in part conducted by researchers from EMBL-EBI.<\/p>\n","protected":false},"author":120,"featured_media":35640,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2,17591],"tags":[1025,1331,1329],"embl_taxonomy":[2278],"class_list":["post-35622","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science","category-science-technology","tag-coronavirus","tag-covid-19","tag-sars-cov-2","embl_taxonomy-covid-19"],"acf":{"featured":true,"show_featured_image":true,"color":"#007B53","link_color":"#fff","article_intro":" Summary of evidence from the U.K.<\/p>\n","related_links":[{"link_description":"EMBL and COVID-19","link_url":"https:\/\/www.embl.org\/topics\/coronavirus\/"}],"article_sources":[{"source_description":" Andrew Rambaut et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations, published online on 20 December 2020<\/p>\n","source_link_url":"https:\/\/virological.org\/t\/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations\/563"},{"source_description":" COVID-19 Genomics UK Consortium<\/p>\n","source_link_url":"https:\/\/www.cogconsortium.uk\/"},{"source_description":" B.1.1.7 report<\/p>\n","source_link_url":"https:\/\/cov-lineages.org\/global_report_B.1.1.7.html"},{"source_description":" Public Health England, Investigation of novel SARS-COV-2 variant<\/p>\n","source_link_url":"https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/947048\/Technical_Briefing_VOC_SH_NJL2_SH2.pdf"},{"source_description":" Erik Volz et al. Report 42 – Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data, published online 31 December 2020<\/p>\n","source_link_url":"https:\/\/www.imperial.ac.uk\/mrc-global-infectious-disease-analysis\/covid-19\/report-42-sars-cov-2-variant\/"},{"source_description":" Nicholas Davies et al. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012\/01 in England, published online 23 December 2020<\/p>\n","source_link_url":"https:\/\/cmmid.github.io\/topics\/covid19\/uk-novel-variant.html"},{"source_description":" Public Health England, Investigation of novel SARS-COV-2 variant – Technical Briefing 3<\/p>\n","source_link_url":"https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/950823\/Variant_of_Concern_VOC_202012_01_Technical_Briefing_3_-_England.pdf"},{"source_description":" Prime Minister’s Office Press release: Prime Minister announces national lockdown, 4 January 2021<\/span><\/p>\n","source_link_url":"https:\/\/www.gov.uk\/government\/news\/prime-minister-announces-national-lockdown"},{"source_description":" Moritz Gerstung et al. Lineage-specific growth of SARS-CoV-2 B.1.1.7 during the English national lockdown; published online 1 December 2020<\/p>\n","source_link_url":"https:\/\/virological.org\/t\/lineage-specific-growth-of-sars-cov-2-b-1-1-7-during-the-english-national-lockdown\/575"},{"source_description":" Kara Steel &Hannah Donnarumma; Coronavirus (COVID-19) Infection Survey, UK; published 8 January 2021<\/p>\n","source_link_url":"https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/coronaviruscovid19infectionsurveypilot\/8january2021"},{"source_description":" Statens Serum Institut; New status of the occurrence of cluster B.1.1.7 in Denmark; published 2 January 2021<\/p>\n","source_link_url":"https:\/\/www.ssi.dk\/aktuelt\/nyheder\/2021\/ny-status-pa-forekomst-af-cluster-b117-i-danmark"},{"source_description":" Nicole L.<\/span>\u00a0Washington et al. S gene dropout patterns in SARS-CoV-2 tests suggest spread of the H69del\/V70del mutation in the US; publishde online 30 December 2020<\/span><\/p>\n","source_link_url":"https:\/\/www.medrxiv.org\/content\/10.1101\/2020.12.24.20248814v1"}],"in_this_article":[{"heading_description":"German version","anchor":"#german"},{"heading_description":"French version","anchor":"#french"},{"heading_description":"Italian version","anchor":"#italian"},{"heading_description":"Spanish version","anchor":"#spanish"}],"youtube_url":"","mp4_url":"","video_caption":"","press_contact":"EMBL Generic","embl_taxonomy_term_who":false,"embl_taxonomy_term_what":false,"embl_taxonomy_term_where":false,"vf_locked":false,"source_article":false},"embl_taxonomy_terms":[{"uuid":"a:3:{i:0;s:36:\"302cfdf7-365b-462a-be65-82c7b783ebf7\";i:1;s:36:\"a5d0c484-f12a-4a27-93cc-85e3a6d79c09\";i:2;s:36:\"5683518e-43cd-4740-8583-31a65ef324d3\";}","parents":[],"name":["COVID-19"],"slug":"covid-19","description":"What > Topics > COVID-19"}],"yoast_head":"\n
\n\n\nDie SARS-CoV-2 B.1.1.7-Linie <\/h1>\n\n\n\n
Zusammenfassung der Erkenntnisse aus Gro\u00dfbritannien<\/h2>\n\n\n\n
\n\n\nLe variant B.1.1.7 du SARS-CoV-2<\/h1>\n\n\n\n\n<\/div><\/div>\n\n\n\n
R\u00e9sum\u00e9 des donn\u00e9es au Royaume-Uni.<\/h2>\n\n\n\n
\n\n\nLa variante SARS-CoV-2 B.1.1.7<\/h1>\n\n\n\n
Sintesi delle evidenze dal Regno Unito<\/h2>\n\n\n\n
\n\n\nLa variante de SARS-CoV-2 B.1.1.7<\/h1>\n\n\n\n
Resumen de la evidencia que llega del Reino Unido<\/h2>\n\n\n\n